BCM
PTCT icon

BlueCrest Capital Management’s PTC Therapeutics PTCT Stock Holding History

BlueCrest Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-30,192
Closed -$817K – 1746
2018
Q1 		$817K Buy
+30,192
New +$765K 0.03% 549

Other funds holding PTCT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BlueCrest Capital Management's PTCT Position: Q2 2018 in Review

BlueCrest Capital Management sold out of PTC Therapeutics (PTCT) in Q2 2018, closing a stake of 30,192 shares — an estimated $817K sold.

BlueCrest Capital Management first reported a position in PTCT in Q1 2018 and held it in 1 quarter. The position peaked at $817K in Q1 2018. 166 funds tracked by Wall St. Rank hold PTCT as of Q2 2018.

  • BlueCrest Capital Management reported no remaining PTC Therapeutics position as of Q2 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 30,192 PTC Therapeutics shares in Q2 2018, an estimated $817K.
  • BlueCrest Capital Management first reported a position in PTC Therapeutics in Q1 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's PTC Therapeutics position peaked at $817K in Q1 2018.
  • 166 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2018.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.